Description
An inhibitor of KSR-dependent MAPK signaling; inhibits ATPbiotin binding to KSR2 in KSR2-MEK1 complexes (IC50 = 120 nM); stabilizes KSR2 in an inactive state; reduces interactions between B-RAF and KSR2-MEK1 complexes; inhibits KSR-stimulated phosphorylation of MEK and ERK in HEK293H cells at 5 μM; enhances the efficacy of trametinib, further reducing cell viability in K-Ras mutant HCT116 and A549 cell lines, but not B-RAF mutant SK-MEL-239 and A375 cell lines, at 1 μM
Formal name: 6,7-dimethoxy-N-(2-methyl-4-phenoxyphenyl)-4-quinazolinamine, monohydrochloride
Synonyms:
Molecular weight: 423.9
CAS: 2002381-31-7
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Cancer|Cell Signaling|ERK/MAPK Signaling||Research Area|Cancer|Cell Signaling|GTPases